Abstract
The unbound fraction in serum f u , is a critical parameter in describing and understanding the pharmacokinetics of NSAIDs. We compared f u for 6 different NSAIDs using ultrafiltration of pooled serum at pH 7.4 and 24C. Measurements covered a wide concentration range in order to define binding affinity and number of binding sites. HPLC was used to measure drug concentrations in serum and ultrafiltrate. Direct injection of ultrafiltrate and serum (diluted 250X) permitted quantitation down to approximately 70 nM for most of the NSAIDs, i.e., approximately 15–20 ng/ml. Assuming binding only to albumin, the data were fitted to a model of two classes of binding sites with dissociation constants K1 and K2. The lowest K1 (highest affinity) was found with flurbiprofen, 0.0658 μM, the highest with ketoprofen, 5.23 μM, an 80-fold difference. At low drug concentrations, f u becomes virtually constant and approaches a lower limit, \({\text{f}}_u^{\min } \). The following \({\text{f}}_u^{\min } \) values were calculated: diclofenac 0.21% fenoprofen 0.25%, flurbiprofen 0.022%, ketoprofen 0.52%, naproxen 0.039%, and tolmetin 0.37%. Thus the least bound NSAID, ketoprofen, had a value 24-fold that of the most highly bound, flurbiprofen. The NSAIDs also differed widely with regard to the extent of variation in f u within the range of therapeutic concentrations, and hence with regard to their potential as displacers of other drugs.
Similar content being viewed by others
REFERENCES
S. Øie and T. N. Tozer. Effect of altered plasma protein binding on apparent volume of distribution. J. Pharm. Sci. 68:1203–1205 (1979).
S. Øie, T. W. Guentert, and T. N. Tozer. Effect of saturable binding on the pharmacokinetics of drugs: a simulation. J. Pharm. Pharmacol. 32:471–477 (1980).
J. H. Lin, D. M. Cocchetto, and D. E. Duggan. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin. Pharmacokin. 12:402–432 (1987).
J. V. Willis, M. J. Kendall, and D. J. Jack. A study of the effect of aspirin on the pharmacokinetics of oral and intravenous diclofenac sodium. Eur. J. Clin. Pharmacol. 18:415–418 (1980).
G. Levy. Effect of plasma protein binding of drugs on duration and intensity of pharmacological activity. J. Pharm. Sci. 65:1264–1265 (1976).
A. S. Joshi, H. J. Pieniaszek, C. Y. Quon, and S-Y. P. King. Plasma protein binding of highly bound drugs: Implications of radiochemical impurities. J. Pharm. Sci. 83:1187–1188 (1994).
A. Mukherjee, V. G. Hale, O. Borga, and R. Stein. Predictability of the clinical potency of NSAIDs from the preclinical pharmacodynamics in rats. Inflamm. Res. 45:531–540 (1996).
R. H. Hook, H. Boxenbaum, G. A. Thompson, and R. A. Okerholm. Human serum and plasma protein binding of enoximone and its sulfoxide metabolite. J. Pharm. Sci. 77:1012–1017 (1988).
G. Scatchard. The attraction of proteins for small molecules and ions. Ann. N.Y. Acad. Sci. 51:660–672 (1949).
Ø. Hundal, H. E. Rugstad, and G. Husby. Naproxen free plasma concentrations and unbound fractions in patients with osteoarthritis: relation to age, sex, efficacy, and adverse events. Ther. Drug Monit. 13:478–484 (1991).
K. M. Piafsky and O. Borgå. Plasma protein binding of basic drugs. II Importance of α1-acid glycoprotein for interindividual variation. Clin. Pharmacol. Ther. 22:545–549 (1977).
J.-M. Chamouard, J. Barre, S. Urien, G. Houin, and J-P. Tillement. Diclofenac binding to albumin and lipoproteins in human serum. Biochem. Pharmacol. 34:1695–1700 (1985).
K. K. H. Chan, K. H. Vyas, and K. D. Brandt. In vitro protein binding of diclofenac sodium in plasma and synovial fluid. J. Pharm. Sci. 76:105–108 (1987).
W. Reiss, H. Stierlin, P. Degen, J. W. Faigle, A. Gérardin, J. Moppert, A. Sallman, K. Schmid, A. Schweizer, M. Sulc, W. Theobald, and J. Wagner. Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren. Scand. J. Rheumatol. Suppl. 22:17–29 (1978).
V. A. John. The pharmacokinetics and metabolism of diclofenac sodium (Voltarol®) in animals and man. Rheumatol. Rehabil. Suppl. 2:22–37 (1979). (Proceedings of an International Symposium, Tangier, March 1978.)
A. Rubin, P. Warrick, R. L. Wolen, S. M. Chernish, A. S. Ridolfo, and C. M. Gruber Jr. Physiological disposition of fenoprofen in man. III. Metabolism and protein binding of fenoprofen. J. Pharmacol. Exp. Ther. 183:449–457 (1972).
P. C. Risdall, S. S. Adams, E. L. Crampton, and B. Marchant. The disposition and metabolism of flurbiprofen in several species including man. Xenobiotica 8:691–704 (1978).
L. Aarons, R. Salisbury, M. Alam-Siddiqi, L. Taylor, and D. M. Grennan. Plasma and synovial fluid kinetics of flurbiprofen in rheumatoid arthritis. Br. J. Clin. Pharmacol. 21:155–163 (1986).
G. J. Szpunar, K. S. Albert, and J. G. Wagner. Pharmacokinetics of flurbiprofen in man II. Plasma protein binding. Res. Commun. Chem. Pathol. Pharmacol. 64:17–30 (1989).
M. P. Knadler, D. C. Brater, and S. D. Hall. Plasma protein binding of flurbiprofen: Enantioselectivity and influence of pathophysiological status. J. Pharmacol. Exp. Ther. 249:378–385 (1989).
M. P. Knadler, D. C. Brater, and S. D. Hall. Stereoselective disposition of flurbiprofen in uraemic patients. Br. J. Clin. Pharmacol. 33:377–383 (1992).
R. Blouin, I. Chaudhary, K. Nishihara, and S. Cox. The effects of liver and renal disease on stereoselective serum binding of flurbiprofen. Br. J. Clin. Pharmacol. 35:62–64 (1993).
P. J. Hayball, R. L. Nation, F. Bochner, J. L. Newton, R. A. Massy-Westropp, and D. P. Hamon. Plasma protein binding of ketoprofen enantiomers in man: method development and its application. Chirality. 3:460–466 (1991).
A. Mortensen, E. B. Jensen, P. B. Petersen, S. Husted, and F. Andreasen. The determination of naproxen by spectrofluorometry and its binding to serum proteins. Acta Pharmacol. Toxicol. 44:277–283 (1979).
R. A. Upton, R. L. Williams, J. Kelly, and R. M. Jones. Naproxen pharmacokinetics in the elderly. Br. J. Clin. Pharmacol. 18:207–214 (1984).
R. Runkel, E. Forchielli, H. Sevelius, M. Chaplin, and E. Segre. Nonlinear plasma level response to high doses of naproxen. Clin. Pharmacol. Ther. 15:261–266 (1974).
J. C. Ojingwa, H. Spahn-Langguth, and L. Z. Benet. Reversible binding of tolmetin, zomepirac, and their glucuronide conjugates to human serum albumin and plasma. J. Pharmacokin. Biopharm. 22:19–40 (1994).
H. Kurz, H. Trunk, and B. Weitz. Evaluation of methods to determine protein-binding of drugs. Equilibrium dialysis, ultrafiltration. ultracentrifugation, gel filtration. Arzneim. Forsch. 27:1373–1380 (1977).
K. Tegnér, O. Borgå, and I. Svensson. Protein binding of enprofylline. Eur. J. Clin. Pharmacol. 25:703–708 (1983).
M. Brinkschulte and U. Breyer-Pfaff. Binding of tricyclic antidepressants and perazine to human plasma. Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharmakol. 308:1–7 (1979).
C. B. Kristensen. Imipramine serum protein binding in healthy subjects. Clin. Pharmacol. Ther. 34:689–694 (1983).
O. G. Nilsen, L. Storstein, and S. Jacobsen. Effect of heparin and fatty acids on the binding of quinidine and warfarin in plasma. Biochem. Pharmacol. 26:22–235 (1977).
P. K. M. Lunde, A. Rane, S. J. Yaffe, and F. Sjöqvist. Plasma protein binding of diphenylhydantoin in man. Clin. Pharmacol. Ther. 11:846–855 (1970).
Ø. Hundal and H. E. Rugstad. Determination of free concentration of piroxicam and naproxen in plasma. The influence of experimental conditions in equilibrium dialysis. Fund. Clin. Pharmacol. 5:275–283 (1991).
G. M. Pacifici and A. Viani. Methods of determining plasma and tissue binding of drugs. Clin. Pharmacokin. 23:449–468 (1992).
L. J. Aarons and M. Rowland. Kinetics of drug displacement interactions. J. Pharmacokin. Biopharm. 9:181–190 (1981).
R. Runkel, M. D. Chaplin, H. Sevelius, E. Ortega, and E. Segre. Pharmacokinetics of naproxen overdoses. Clin. Pharmacol. Ther. 20:269–277 (1976).
G. J. Szpunar, K. S. Albert, G. G. Bole, J. N. Dreyfus, G. F. Lockwood, and J. G. Wagner. Pharmacokinetics of flurbiprofen in man I. Area/dose relationships. Biopharm. Drug Dispos. 8:273–283 (1987).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Borgå, O., Borgå, B. Serum Protein Binding of Nonsteroidal Antiinflammatory Drugs: A Comparative Study. J Pharmacokinet Pharmacodyn 25, 63–77 (1997). https://doi.org/10.1023/A:1025719827072
Published:
Issue Date:
DOI: https://doi.org/10.1023/A:1025719827072